Skip to main content

Table 3 Summary of the clinical measures, biomarkers, and cell counts among the four groups of COPD patients identified from the results of Figure 2: each group combines GOLDCD, EMPHETCD and FV950, with either BMI (Group I), DWALK (Group II), AGE (Group III) or Phlegm (Group IV).

From: A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease

 

Group-IA

(n = 25)

Group-IB, (n = 23)

p- values

Group-IIA

(n = 21)

Group-IIB ,

(n = 32)

p- values

Group -IIIA (n = 15)

Group-IIIB

(n = 28)

p-values

Group-IVA

(n = 20)

Group-IVB

(n = 26)

p- values

Age

65.4

65.4

-

63.9

65.4

-

58.73

68.7

***

63

65.96

-

Lung Function

  

-

  

-

  

-

  

-

FEV1

1.72

0.89

***

1.7

0.9

***

1.72

0.93

**

1.79

0.9

***

FEV1/FVC (%)

57.88

32.43

***

55.0

32.5

***

56.53

33.93

***

57.1

33.04

***

FEV1 reversibility (%)

7.64

4.73

***

11.5

7.2

***

11.62

5.93

***

10.4

5.5

***

Radiologist Emphysema

  

-

  

-

  

-

  

-

Emphysema severity

1.2

4.2

***

1.3

4.2

***

1.336

3.7

***

1.275

4.2

***

Densitometric Emphysema

  

-

  

-

  

-

  

-

Emphysema at -950 HU

6.98

33.42

***

6.6

31.7

***

7.71

28.09

***

7.06

33.42

***

Airflow Obstruction

  

-

  

-

  

-

  

-

GOLD Stage

2

3.3

***

2.0

3.3

***

2

3.2

***

2

3.3

***

Body Mass Index

30.76

21.21

***

27.3

24.2

*

29.87

25.8

-

28.67

24.42

*

Chronic Bronchitis (ATS_CB)

1 = no-CB

Phelgm

1 = 24%

1 = 30.4%

-

1 = 85.7%

1 = 62.5%

-

1 = 6.7%

1 = 37%

-

1-100%

1 = 46.2%

***

1 = no chronic phlegm

1 = 56%

1 = 35%

-

1 = 62%

1 = 41%

-

1 = 66.6%

1 = 33%

-

1-100%

1 = 0%

***

6 Minute Walk Distance

428.32

330.02

**

508.8

273.9

***

438.97

321.83

**

462.59

322.9

**

Exacerbations 0 = no-Exacerbations

0 = 68%

0 = 34.8%

-

0 = 71.4%

0 = 28.1%

**

0 = 60%

0 = 37%

-

0 = 70%

0 = 38.5%

*

CCL6

7.3

6.33

-

7.0

6.8

-

6.19

6.73

-

8.64

6.9

-

IL6

5.65

20.2

-

4.3

18.6

-

2.79

6.89

**

3.72

18.53

-

IL8

8.88

10.77

-

8.3

9.4

-

7.5

10.28

*

9.8

10.65

-

TNFa

26.99

160.32

-

31.7

162.9

-

2.35

60.44

-

24.14

142.3

-

CCL18

130.3

117.59

-

126.9

124.4

-

115.8

117.94

-

134

126.19

-

CRPHS

10.4

9.6

-

9.9

9.5

-

5.7

9.72

-

510

8.5

-

FIBRINOG

494.9

499.1

-

481.0

506.2

-

456.8

498.58

-

510.8

489.84

-

SPD

129.64

110.94

-

124.9

119.1

-

79.73

116.3

*

138.76

109.7

-

mMRC

3

2.09

**

1.0

2.4

***

1.21

2.04

*

1.1

2.04

*

SGRQ

43.29

55.55

**

35.9

56.0

***

41.8

52.87

*

36

57.73

***

FFMI

19.53

16.13

***

18.5

17.1

*

18.48

17.8

-

18.83

17.15

*

% Fat (Tissue)

34.92

29.08

**

31.0

31.7

-

35.96

31.94

-

32.69

31.25

-

   

-

  

-

  

-

  

-

Neutrophils, % Neut_Blq

61.38

64.87

-

60.7

67.0

**

61.34

66.69

*

62.08

65.55

-

Eosinophils, % Eos blq

3

3.1

-

3.5

3.1

-

2.48

2.92

-

3.26

3.3

-

Lymphocytes, % lymhblq

28.63

24.84

-

28.6

23.2

*

29.19

23.55

*

27.77

23.688

-

  1. * = p-value < 0.05; ** = p-value < 0.01; *** = p-value < 0.0001; - = not significant